A prospective, multi-centre, phase IV study to evaluate safety and efficacy of SomatoRelTM (recombinant human growth hormone manufactured by Reliance Life Sciences Pvt. Ltd.) in growth hormone deficient children
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Somatropin (Primary)
- Indications Growth disorders; Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Reliance Life Sciences
- 02 Dec 2020 Status changed from not yet recruiting to recruiting.
- 30 Jul 2020 New trial record